Global Opportunities Trust reaffirms successful value and absolute-return strategy (LON: GOT) 12 December 2025
Prediction markets move into the mainstream as trading surges | Ruffer Investment Company 12 December 2025
Workspace Group PLC (WKP.L) Stock Analysis: Navigating Challenges with a 25% Potential Upside 19 December 2025
Wizz Air Holdings PLC (WIZZ.L) Stock Report: Navigating the Skies with a 5.21% Potential Upside 19 December 2025
Trustpilot Group PLC (TRST.L): Analyst Consensus Reveals 84% Potential Upside for Investors 19 December 2025
Global Opportunities Trust reaffirms successful value and absolute-return strategy (LON: GOT) 12 December 2025
Prediction markets move into the mainstream as trading surges | Ruffer Investment Company 12 December 2025
Workspace Group PLC (WKP.L) Stock Analysis: Navigating Challenges with a 25% Potential Upside 19 December 2025
Wizz Air Holdings PLC (WIZZ.L) Stock Report: Navigating the Skies with a 5.21% Potential Upside 19 December 2025
Trustpilot Group PLC (TRST.L): Analyst Consensus Reveals 84% Potential Upside for Investors 19 December 2025
GlaxoSmithKline plc outcome of the FDA advisory committee on mepolizumab for the treatment of COPD patients 26 July 2018
Global Opportunities Trust reaffirms successful value and absolute-return strategy (LON: GOT) 12 December 2025
Prediction markets move into the mainstream as trading surges | Ruffer Investment Company 12 December 2025
Workspace Group PLC (WKP.L) Stock Analysis: Navigating Challenges with a 25% Potential Upside 19 December 2025
Wizz Air Holdings PLC (WIZZ.L) Stock Report: Navigating the Skies with a 5.21% Potential Upside 19 December 2025
Trustpilot Group PLC (TRST.L): Analyst Consensus Reveals 84% Potential Upside for Investors 19 December 2025